---
title: "Weekly Recap | Caris Life Sciences +4.71%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302949484.md"
description: "Caris Life Sciences (CAI) gained 4.71% this week to close at $32, outperforming the S&P 500 by about 5.18 percentage points. Trading was choppy: the stock dipped to $30.62 on Monday, rallied to $32.75 on Wednesday, then pulled back to around $31 before settling at $32 on Friday. Weekly amplitude was 8.48%. Average daily volume of about 2.52m shares was 42.83% below the 60-session median, pointing to a quiet, low-volume week."
datetime: "2026-10-24T06:00:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302949484.md)
  - [en](https://longbridge.com/en/news/302949484.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302949484.md)
generator: "portal-rs"
---

# Weekly Recap | Caris Life Sciences +4.71%, consensus target above spot

## The Week

Caris Life Sciences (CAI) gained 4.71% this week to close at $32, outperforming the S&P 500 by about 5.18 percentage points. Trading was choppy: the stock dipped to $30.62 on Monday, rallied to $32.75 on Wednesday, then pulled back to around $31 before settling at $32 on Friday. Weekly amplitude was 8.48%. Average daily volume of about 2.52m shares was 42.83% below the 60-session median, pointing to a quiet, low-volume week.

## Key Events

The week’s main thread was brand and institutional positioning. On 19 October, the company launched a new national commercial featuring Jordan Spieth, highlighting the role of AI in early-stage cancer detection; the same week, a US research roundup also mentioned the name. On 23 October, E. Ohman J or Asset Management AB bought 125,000 shares, a marginal increase in institutional exposure. No company-level earnings or major regulatory updates landed during the week.

## Analyst Ratings

Of the 14 firms covering CAI, 9 rate it buy, 4 hold and 1 overweight, with no underweight or sell ratings; consensus is buy. The consensus target of $32.08 sits about 24.04% above spot, with a wide range from $22 to $38. Within the biotech industry, the stock ranks 74th out of 511 names, placing it in the upper-middle tier.

## The Week Ahead

The key date ahead is 4 November, when Caris Life Sciences reports fiscal Q3 2026 results after the close. Estimates call for EPS of $0.0305 and revenue of $255m. Before that, US macro data next week includes durable goods orders, new home sales, FHFA house prices and consumer confidence, which could affect risk appetite for biotech names.

## In Short

The week leaves a clear tension: consensus rating is buy and the consensus target sits above spot by about 24%, but valuation is not cheap at 15.28x book and 86x earnings. The latest session’s fund flow shows large and medium orders as net buyers, while retail-sized flow is a net seller. A quiet, low-volume gain alongside firmer institutional positioning makes the Q3 report the next real test: can results justify the current multiple and the macro backdrop for growth names.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CAI.US](https://longbridge.com/en/quote/CAI.US.md)

## Related News & Research

- [Piper Sandler Remains a Hold on Caris Life Sciences, Inc. (CAI)](https://longbridge.com/en/news/304473224.md)
- [Caris Life Sciences' Q3 revenue rises on molecular profiling strength](https://longbridge.com/en/news/304334794.md)
- [Goldman Sachs Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)](https://longbridge.com/en/news/304455891.md)
- [Is Bandwidth (BAND) Undervalued Following Its Profit Swing And Raised Outlook?](https://longbridge.com/en/news/304749372.md)
- [How Strong Earnings At ADP Have Changed Its Investment Story](https://longbridge.com/en/news/304750300.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**